

AGENDA

**Uniform Formulary Beneficiary Advisory Panel (BAP)
25 September 2019 @ 9:00 AM**

**Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting (BAP members report no later than 8:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

The P&T Committee made recommendations for the following drugs/drug classes during the August 2019 meeting:

- **Drug Class Reviews**
 - *High-Potency Topical Corticosteroids*
 - *Multiple Sclerosis: Interferons and Methyl Fumarate*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *alpelisib (Piqray) – Oncological Agent for breast cancer*
 - *amifampridine (Ruzurgi) – Miscellaneous Neurological Agent for Lambert-Eaton myasthenic syndrome (LEMS)*
 - *amphetamine sulfate orally disintegrating IR tablet (Evekeo ODT) – Attention Deficit Hyperactivity Disorder (ADHD)*
 - *dolutegravir/lamivudine (Dovato) – Single-tablet regimen (STR) antiretroviral for Human Immunodeficiency Virus (HIV)*
 - *drospirenone (Slynd) – Progestogen-only contraceptive agent*
 - *erdafitinib (Balversa) – Oral Oncological Agent for urothelial cancer*
 - *galcanezumab-gnlm 100 mg injection (Emgality) – Migraine Agents: Calcitonin gene-related peptide (CGRP) inhibitors for cluster headache*

- *halobetasol propionate 0.01%/tazarotene 0.045% (Duobrii) – Combination product for Plaque Psoriasis*
- *immunoglobulin subcutaneous injection (Cutaquig) – Immunoglobulin for Immune Deficiency Disorders*
- *mepolizumab injection (Nucala) – Miscellaneous Pulmonary I Agent for severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA)*
- *methylphenidate extended-release sprinkle capsules (Adhansia XR) – ADHD*
- *methylphenidate extended-release sprinkle nighttime dosing capsules (Jornay PM) – ADHD*
- *risankizumab-rzaa injection (Skyrizi) – Targeted Immunomodulatory Biologic (TIB) for Plaque Psoriasis*
- *rosuvastatin sprinkle capsules (Ezallor Sprinkle) – Antilipidemics-I*
- *solriamfetol (Sunosi) – Wakefulness Promoting Agent*
- *tafamidis meglumine (Vyndaqel) – Miscellaneous Neurological Agents for cardiomyopathy associated with hereditary transthyretin-mediated amyloidosis (ATTR-CM)*
- *triclabendazole (Egaten) – Antiinfectives: Anthelmintics for fascioliasis*

➤ **Utilization Management Issues**

➤ ***Prior Authorization Criteria—New Criteria***

- *Antibiotics: Tetracyclines – Doxycycline hyclate extended-release 80 mg – Oral tetracycline antibiotic for acne vulgaris or rosacea*
- *Oral Oncologic Agents: alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), and crizotinib (Xalkori)*
- *Vitamins: Prenatal – Prenatal multivitamin (Azesco)*
- *Cardiovascular Agents Miscellaneous: Droxidopa (Northera)*

➤ ***Prior Authorization Criteria—Updated Criteria***

- *Gastrointestinal-2 Agents: telotristat ethyl (Xermelo)*
- *Neurological Agents Miscellaneous: amifampridine (Firdapse)*
- *Parkinson’s Agents: levodopa inhalation powder (Inbrija)*
- *ADHD – Wakefulness Promoting Agents: Wakefulness Promoting Agents: sodium oxybate (Xyrem)*

- *Corticosteroids – Immune Modulators: Atopic Dermatitis: dupilumab (Dupixent)*
- *Cystic Fibrosis Agents: tezacaftor/ivacaftor (Symdeko)*
- *Hematological agents: Platelets: avatrombopag (Doptelet)*
- *Immunosuppressives: belimumab (Benlysta)*
- *Oncological Agents: Acute Myelogenous Leukemia: ivosidenib (Tibsovo)*
- *Targeted Immunomodulatory Biologics (TIBs) – Non-Tumor Necrosis Factor (TNF) Inhibitors: apremilast (Otezla) and adalimumab (Humira)*
- *Weight Loss Agents: liraglutide 3 mg injection (Saxenda)*

➤ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.